Prognostic value of LDH and α-HBDH dynamic levels for 1-year overall survival and progression-free survival in patients with extensive-stage small-cell lung cancer treated with chemoimmunotherapy
LDH and α-HBDH serve as key prognostic biomarkers in ES-SCLC patients undergoing first-line chemoimmunotherapy. We established clinically validated thresholds, which can guide treatment by identifying patients with elevated or insufficiently declining levels as high-risk, thereby supporting early and targeted therapeutic intervention.
Authors
- Yanqin Yang (ORCID: https://orcid.org/0000-0003-2779-5504)
- Shuangqing Lu
- Wanjing Li (ORCID: https://orcid.org/0009-0001-1777-274X)
- Ke Zhao (ORCID: https://orcid.org/0000-0002-8262-4989)
- Guochang Du
- H. Zhu
- Jinming Yu
Institutions
- Shandong University (CN)
- Shandong First Medical University (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2026-01-12
- DOI
- https://doi.org/10.3389/fonc.2025.1721581
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Natural Science Foundation of Shandong Province
- National Science and Technology Major Project